BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $423,287,169 | -19.2% | 6,218,410 | -3.1% | 0.02% | -14.8% |
| Q2 2023 | $523,590,575 | +12.4% | 6,414,193 | +2.2% | 0.03% | +3.8% |
| Q1 2023 | $465,769,717 | -55.8% | 6,278,066 | -50.6% | 0.03% | -16.1% |
| Q4 2022 | $1,052,779,884 | +134.7% | 12,702,460 | +704.2% | 0.03% | +10.7% |
| Q3 2022 | $448,580,000 | -17.5% | 1,579,507 | +0.7% | 0.03% | -15.2% |
| Q2 2022 | $543,628,000 | -21.3% | 1,568,279 | -1.7% | 0.03% | -2.9% |
| Q1 2022 | $691,188,000 | -16.9% | 1,596,130 | -0.8% | 0.03% | -12.8% |
| Q4 2021 | $831,993,000 | +11.9% | 1,608,213 | +4.8% | 0.04% | 0.0% |
| Q3 2021 | $743,550,000 | +35.8% | 1,534,453 | +26.2% | 0.04% | +34.5% |
| Q2 2021 | $547,374,000 | +59.9% | 1,215,684 | +35.7% | 0.03% | +45.0% |
| Q1 2021 | $342,268,000 | +20.0% | 896,154 | -0.2% | 0.02% | +17.6% |
| Q4 2020 | $285,268,000 | +30.4% | 898,339 | +1.7% | 0.02% | +13.3% |
| Q3 2020 | $218,731,000 | -11.1% | 882,940 | -5.2% | 0.02% | -16.7% |
| Q2 2020 | $245,974,000 | +41.0% | 931,472 | +1.2% | 0.02% | +20.0% |
| Q1 2020 | $174,509,000 | -10.6% | 920,310 | +3.5% | 0.02% | +15.4% |
| Q4 2019 | $195,232,000 | +10.6% | 889,397 | -1.4% | 0.01% | 0.0% |
| Q3 2019 | $176,510,000 | -8.5% | 902,082 | -2.5% | 0.01% | -7.1% |
| Q2 2019 | $192,853,000 | +5.7% | 924,997 | +0.7% | 0.01% | 0.0% |
| Q1 2019 | $182,436,000 | +39.3% | 918,844 | +1.5% | 0.01% | +16.7% |
| Q4 2018 | $130,989,000 | -33.9% | 905,118 | -6.8% | 0.01% | -20.0% |
| Q3 2018 | $198,153,000 | +42.0% | 970,846 | +2.9% | 0.02% | +25.0% |
| Q2 2018 | $139,561,000 | -6.8% | 943,309 | -4.9% | 0.01% | -7.7% |
| Q1 2018 | $149,787,000 | +14.3% | 991,714 | -2.0% | 0.01% | +18.2% |
| Q4 2017 | $131,037,000 | +9.0% | 1,011,440 | +1.7% | 0.01% | +10.0% |
| Q3 2017 | $120,185,000 | +2.8% | 994,226 | -0.1% | 0.01% | 0.0% |
| Q2 2017 | $116,891,000 | +16.2% | 994,739 | +0.5% | 0.01% | +11.1% |
| Q1 2017 | $100,590,000 | +1.4% | 989,661 | +2.6% | 0.01% | 0.0% |
| Q4 2016 | $99,174,000 | -8.5% | 964,479 | -2.5% | 0.01% | -18.2% |
| Q3 2016 | $108,355,000 | -5.1% | 989,546 | -2.3% | 0.01% | -8.3% |
| Q2 2016 | $114,185,000 | +19.8% | 1,012,538 | +0.4% | 0.01% | +20.0% |
| Q1 2016 | $95,298,000 | +7.1% | 1,008,325 | +2.0% | 0.01% | 0.0% |
| Q4 2015 | $89,003,000 | +0.6% | 988,916 | +3.4% | 0.01% | 0.0% |
| Q3 2015 | $88,444,000 | -8.8% | 956,637 | -2.8% | 0.01% | 0.0% |
| Q2 2015 | $96,940,000 | -7.4% | 984,450 | -5.7% | 0.01% | -9.1% |
| Q1 2015 | $104,682,000 | +9.8% | 1,043,797 | +1.1% | 0.01% | +22.2% |
| Q4 2014 | $95,363,000 | -0.3% | 1,032,082 | +1.0% | 0.01% | -10.0% |
| Q3 2014 | $95,631,000 | – | 1,022,287 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |